Insulet's Insulin Delivery System Shows Durable Glycemic Control With One Year of Use

Insulet Corporation PODD presented data from the pivotal trial extension phase of the Omnipod 5 Automated Insulin Delivery System.
Omnipod 5 is a tubeless, wearable system that continuously adapts insulin delivery based on glucose levels and trends.
Data showed Omnipod 5 significantly improved time in range and reduced HbA1c patients aged 6-70 years with type 1 diabetes over a period of 12 months.
The data was presented at EASD 2021, the annual meeting of the European Association for the Study of Diabetes.
After three months of system use, adults and adolescents had a decrease in HbA1c from 7.2% to 6.8%.
This decrease was maintained after a total of 12 months of use, with mean HbA1c remaining at 6.8%.
The Omnipod 5 System received breakthrough device designation from the FDA and is currently under premarket review.
Insulet expects to launch Omnipod 5 in limited release in the U.S. late in Q4 of 2021.
Insulet also presented new clinical outcomes data for people with type 1 diabetes using the Omnipod DASH System for 90 days and positive self-management behaviors.
Related: FDA Clears Use Of Eli Lilly's Insulin With Insulet's Infusion Pumps.
Price Action: PODD stock is up 1.42% at $282.93 during the market session on the last check Thursday.